

COPY OF ALLOWED CLAIMS

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of the Claims:

Claims 1-27 (cancelled).

28. (presently amended): A method of making an antibody that specifically binds to phosphatidylserine, said method comprising administering to an animal a pharmaceutical composition comprising an immunologically effective amount of a phosphatidylserine/polypeptide conjugate composition, wherein the phosphatidylserine is covalently coupled to the polypeptide.

29. (previously presented): The method of claim 28, wherein a composition comprising phosphatidylserine/BSA, phosphatidylserine/KLH, phosphatidylserine/BGG, or phosphatidylserine/ β_2 -glycoprotein I conjugate is administered to the animal.

AMENDED
5/25/04

Claims 30-36 (cancelled).

37. (previously presented): The method of claim 29, wherein said polypeptide is β_2 -glycoprotein I.

38. (previously presented): The method of claim 28, wherein the antibody is linked to a detectable label.

39. (previously presented): The method of claim 38, wherein the antibody is linked to a radioactive label, a fluorogenic label, a nuclear magnetic spin resonance label, biotin or an enzyme that generates a detectable product upon contact with a chromogenic substrate.

40. (previously presented): The method of claim 38, wherein the antibody is linked to an alkaline phosphatase, hydrogen peroxidase or glucose oxidase enzyme.

7 41. (previously presented): The method of claim 28, wherein the antibody is a monoclonal antibody.

8 42. (presently amended): A method of making an antibody that specifically binds to phosphatidylserine, said method comprising administering to an animal a pharmaceutical composition comprising an immunologically effective amount of a phosphatidylserine/polypeptide conjugate composition, wherein the phosphatidylserine/polypeptide conjugate composition is not a phosphatidylserine/KLH conjugate composition, and wherein the phosphatidylserine is covalently coupled to the polypeptide.

9 43. (previously presented): The method of claim 42, wherein the pharmaceutical composition comprises a phosphatidylserine/BSA, phosphatidylserine/BGG, or phosphatidylserine/β₂-glycoprotein I conjugate.

10 44. (previously presented): The method of claim 43, wherein said polypeptide is β₂-glycoprotein I.

11 45. (previously presented): The method of claim 42, wherein the antibody is linked to a detectable label.

12 46. (previously presented): The method of claim 45, wherein the antibody is linked to a radioactive label, a fluorogenic label, a nuclear magnetic spin resonance label, biotin or an enzyme that generates a detectable product upon contact with a chromogenic substrate.

13 47. (previously presented): The method of claim 45, wherein the antibody is linked to an alkaline phosphatase, hydrogen peroxidase or glucose oxidase enzyme.

14 48. (previously presented): The method of claim 42, wherein the antibody is a monoclonal antibody.

15

49. (presently amended): A method of making a monoclonal antibody that specifically binds to phosphatidylserine, said method comprising administering to an animal a pharmaceutical composition comprising an immunologically effective amount of a phosphatidylserine/polypeptide conjugate composition, wherein the phosphatidylserine is covalently coupled to the polypeptide.

16

50. (previously presented): The method of claim 49, wherein the pharmaceutical composition comprises a phosphatidylserine/BSA, phosphatidylserine/BGG, or phosphatidylserine/ β_2 -glycoprotein I conjugate.

17

51. (previously presented): The method of claim 50, wherein said polypeptide is β_2 -glycoprotein I.

18

52. (previously presented): The method of claim 49, wherein the antibody is linked to a detectable label.

19

53. (previously presented): The method of claim 52, wherein the antibody is linked to a radioactive label, a fluorogenic label, a nuclear magnetic spin resonance label, biotin or an enzyme that generates a detectable product upon contact with a chromogenic substrate.

20

54. (previously presented): The method of claim 52, wherein the antibody is linked to an alkaline phosphatase, hydrogen peroxidase or glucose oxidase enzyme.